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Pterygium and Associated Ocular
Surface Squamous Neoplasia
Lawrence W. Hirst, MD, MPH; Roy A. Axelsen, BSc, MD, FRCPA; Ivan Schwab, MD
Objective: To measure the rate of histopathologically
identified ocular surface squamous neoplasia (OSSN) in
pterygium specimens.
Methods: All pterygium specimens collected from con-
secutive patients between April 8, 2003, and February
6, 2008, were submitted for histopathologic examina-
tion, and the rate of OSSN was calculated.
Results: The rate of OSSN was 9.8% (52 of 533) in
sequential pterygium specimens.
Conclusions: This rate of unsuspected OSSN suggests
that all specimens of pterygium should be submitted for
histopathologic examination and that patients in whom
OSSN is noted should be examined at more frequent in-
tervals so any clinical OSSN that develops can be iden-
tified at an early stage.
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P TERYGIUM IS A COMMON OCU-lar surface disease in Austra-lia, with a prevalence of 7.3%in a population-based studyin Blue Mountains, New
South Wales, Australia.1 A pathology-
based incidence study2 of ocular surface
squamous neoplasia (OSSN) in the state
of Queensland demonstrated a rate of 1.9
new cases per 100 000 residents. Because
both of these ocular surface conditions are
strongly related to sunlight exposure,3,4 it
could be expected that both might occur
in the same individual.We examined this
hypothesis by using histopathologic ex-
amination to identify OSSN in pterygium
tissue samples removed during surgery.
METHODS
This retrospective study examined the patho-
logic results of excised tissue from all patients
with pterygium who underwent surgery con-
sisting of excision and autoconjunctival trans-
plantation. The procedures were all per-
formed by 1 of us (L.W.H.) between April 8,
2003, and February 6, 2008. The indications
for surgery were primarily the presence of pte-
rygium greater than 3 mm on the cornea, vi-
sion loss attributable to pterygium, and, in some
patients, a concern about the appearance of the
eye. All specimens were submitted for routine
pathologic examination in formalin fixation,
which involved paraffin embedding of the en-
tire pterygium specimen. Multiple serial sec-
tions, 4 µm thick, were cut. Three or 4 sec-
tions stained with hematoxylin-eosin were
mounted on each slide, and 4 slides were ex-
amined per specimen.One pathologist (R.A.A.)
examined all the specimens in an open man-
ner because the interpretations weremade and
documented during the initial pathologic ex-
amination for routine diagnosis of the submit-
ted specimens. If a patient had a pterygium re-
moved from the opposite eye, it was considered
to be a separate event; if a nasal pterygium and
a temporal pterygiumwere excised from 1 eye,
only the first pterygium removed was in-
cluded in this study. Findings of OSSN were
reported as mild dysplasia, moderate dyspla-
sia, severe dysplasia, and carcinoma in situ ac-
cording to an accepted classification.5
All the patients were followed up for at least
1 year after pterygium surgery. The possible dif-
ference in OSSN incidence between primary
and recurrent pterygium specimens was tested
using a 2 test. This study was approved by the
Human Research Ethics Committee of Prin-
cess Alexandra Hospital.
RESULTS
Five hundred thirty-three consecutive pte-
rygium specimens were excised from pa-
tients between April 8, 2003, and Febru-
ary 6, 2008. In 3 patients, there was some
slitlamp evidence of clinical OSSN ex-
pressed as well-demarcated corneal epi-
thelial clouding emanating from the head
of the pterygium. Otherwise, there was no
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clinical suspicion of OSSN. The male to female distribu-
tion of patients was 1.82:1.0, the mean (SD) age was 50
(12.8) years (range, 18-85 years), and the ratio of right
to left eyes was 0.93:1.00. There were no significant dif-
ferences in any of these variables in patients with pte-
rygium and no evidence of OSSN compared with the
group with histopathologic evidence of OSSN.
Fifty-two specimens (9.8%) revealed OSSN, of which
33 (63.5%) were graded as mild dysplasia, 10 (19.2%)
as moderate dysplasia, 5 (9.6%) as severe dysplasia, and
1 (1.9%) as invasive squamous cell carcinoma. In 3 speci-
mens, dysplasia was ungradable. None of the OSSN-
positive specimens were from bilateral pterygium exci-
sions. Forty-six of 437 primary pterygium specimens
(10.5%) and 6 of 96 recurrent pterygium specimens
(6.3%) revealed OSSN. There was no significant differ-
ence between these groups (relative risk, 1.68; 95% con-
fidence interval, 0.74-3.83; P=.20; 21=1.63). No OSSN
was evident in any patients via slitlamp evaluation dur-
ing the 1-year follow-up.
COMMENT
We investigated the frequency of association ofOSSNwith
pterygium specimens. To our knowledge, there have been
no reports of this association. A population-based study2
has identified a rate of 1.9 new cases of OSSN per 100 000
residents per year, but this was thought to be a gross un-
derestimate of the true incidence rate. The much higher
rate of OSSN found in this study may be readily ex-
plained by the common causal association with sun-
light exposure for both diseases.3,4
Pterygium surgery is generally undertaken at a
younger age than is treatment for OSSN,6,7 and so it is
not surprising that few, if any, of these patients had
clinical evidence of OSSN at the time of pterygium
evaluation. The most obvious explanation for the asso-
ciation between these 2 diseases is the common factor
of sunlight exposure. The pathogenic process that may
follow sunlight exposure is likely to be the overexpres-
sion of p53, whereas the role of human papillomavirus
is unclear.8
This high rate of OSSN in patients with pterygium is
sufficient justification for a pathologic audit of all pte-
rygium specimens so that patients can be warned of the
possible recurrence of OSSN at a later time. The results
of this study also suggest that routine examination of pa-
tients with pterygium and histopathologically diag-
nosed OSSN should probably occur at more frequent in-
tervals than might otherwise be undertaken. No data, at
present, indicate whether nonclinical OSSN will ulti-
mately result in clinical disease; however, at least 1 pa-
tient in the present series had invasive squamous cell
carcinoma, which suggests that severe consequences
could result.
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